Can a new infusion drug shrink Hard-to-Treat tumors?
NCT ID NCT07750132
First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This early-stage trial is testing an investigational drug called SM2275 in people with advanced or metastatic solid tumors that have progressed after standard treatment or for which no standard therapy exists. The study aims to find the safest dose, understand how the drug behaves in the body, and look for early signs that it can fight tumors. Participants receive SM2275 by intravenous infusion, and the trial will monitor side effects and immune responses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SM2275, an investigational drug given by intravenous infusion
- What this could lead to
- If SM2275 proves safe and shows antitumor activity, it could become a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
- What could go wrong
- This is an early-phase, first-in-human study, so the drug may not be effective or may cause unexpected side effects. The results will only establish safety and dosing, not proof of benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.